Clinical Trials Directory

Trials / Completed

CompletedNCT01909557

Acetyl-L-Carnitine Supplementation During HCV Therapy With Peg IFN-α2b Plus Ribavirin: Effect on Work Performance.

Effect of Supplementation of Antioxidant Substances and Probiotics in HCV Correlated Liver Disease Treated With Interferon and Ribavirin. Studies on Biochemical and Virological Response and on Quality of Life.

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
62 (actual)
Sponsor
University of Catania · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Accepted

Summary

To assess the effects of Acetyl-L-Carnitine, probiotics and antioxidant nutritional substances administration on work productivity, daily activity, and fatigue in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b and Ribavirin.

Conditions

Interventions

TypeNameDescription
DRUGAcetyl-L-carnitine
DRUGplacebo

Timeline

Start date
2010-01-01
Primary completion
2011-12-01
Completion
2011-12-01
First posted
2013-07-26
Last updated
2013-07-26

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT01909557. Inclusion in this directory is not an endorsement.

Acetyl-L-Carnitine Supplementation During HCV Therapy With Peg IFN-α2b Plus Ribavirin: Effect on Work Performance. (NCT01909557) · Clinical Trials Directory